TABLE 2.
Relative risk of propensity score matched patients developing NDDs after receiving statins
| All NDD combined | AD | Dementia | MS | PD | ALS | |
|---|---|---|---|---|---|---|
| Without statin exposure | ||||||
| # Patients | 8508 | 3151 | 7164 | 203 | 1221 | 72 |
| % | 6.40% | 2.37% | 5.39% | 0.15% | 0.92% | 0.05% |
| With statin exposure | ||||||
| # Patients | 4790 | 1463 | 4029 | 106 | 645 | 33 |
| % | 3.60% | 1.10% | 3.03% | 0.08% | 0.48% | 0.02% |
| Relative risk | 0.56 | 0.46 | 0.56 | 0.52 | 0.53 | 0.46 |
| 95%CI | 0.54 to 0.58 | 0.44 to 0.49 | 0.54 to 0.58 | 0.41 to 0.66 | 0.48 to 0.58 | 0.30 to 0.69 |
| NNT | 35.77 | 78.79 | 42.42 | 1371 | 230.9 | 3410 |
| P‐value | <.001 | <.001 | <.001 | <.001 | <.001 | <.001 |
Abbreviations: AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CI, confidence interval; MS, multiple sclerosis; NDD, neurodegenerative diseases; NNT, number needed to treat; PD, Parkinson's disease.